About Shionogi

Shionogi develops treatments for some of the world's most challenging infectious diseases and rare disorders. With research programmes spanning antimicrobial resistance, HIV, influenza and COVID-19, the company addresses critical unmet medical needs through science led drug discovery. Its portfolio includes novel antibiotics, antiviral medications and therapies for Fragile X syndrome. Founded in 1878 in Osaka, Japan, Shionogi operates globally with a focus on turning scientific excellence into patient outcomes. The company partners with government agencies, biotechnology firms and academic institutions to accelerate drug development and deliver meaningful solutions to communities facing urgent health threats.